The Supreme Court issued a temporary order on Monday extending access to mifepristone, the most commonly used abortion medication in the United States, while litigation over the drug's distribution rules continues. The order preserves mail-order access to the pill, which accounts for the majority of abortions in the country.

The Court's action is procedural and does not constitute a final ruling on the merits of the case. It maintains the status quo established under existing Food and Drug Administration regulations, which had loosened access to mifepristone in recent years to allow prescriptions by telemedicine and delivery by mail.

The temporary extension comes amid ongoing legal challenges from anti-abortion groups and some Republican-led states that have sought to reimpose stricter dispensing requirements on the drug. Lower court decisions have produced conflicting rulings on the extent of the FDA's authority to regulate the pill's distribution.

Separately, the Trump administration has been engaged in outreach to anti-abortion organizations, with a focus on maternal health initiatives as part of efforts to maintain political support from those groups. That effort signals the continued political sensitivity around abortion policy at the federal level even as the courts remain the primary arena for resolving access questions.

International access to mifepristone has also drawn scrutiny from abortion opponents, who have highlighted online networks that provide the drug across borders as a workaround to domestic restrictions. Advocates on both sides expect the Supreme Court's eventual ruling on the underlying case to set significant precedent for how far federal and state governments can go in restricting the medication.